Who Supplies Doxycycline to India from SOUTH SUDAN

Importing finished pharmaceutical formulations containing Doxycycline into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The foreign manufacturer must obtain a No Objection Certificate (NOC) from the Central Drugs Standard Control Organisation (CDSCO) before export. The Indian importer must possess a valid Importer License issued by the Directorate General of Foreign Trade (DGFT). The product must be registered with CDSCO, which involves submitting Form 40 or 41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The registration process typically takes 6–12 months. For Doxycycline formulations under HS Code 30049099, specific requirements include stability data (preferably ICH Zone IV), CoA, and compliance with Indian Pharmacopoeia standards.

Upon arrival in India, each batch of Doxycycline formulations must undergo quality testing at a CDSCO-approved laboratory. The importer must provide a Certificate of Analysis (CoA) and batch-wise stability data. The product must meet Indian Pharmacopoeia standards. Port inspection by customs drug inspectors is mandatory to verify compliance. If a batch fails quality testing, it may be rejected, re-exported, or destroyed, depending on the severity of the non-compliance.

Between 2024 and 2026, the CDSCO has implemented stricter regulations for importing finished pharmaceutical formulations, including Doxycycline. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially affecting the volume of imports. Bilateral agreements with South Sudan have been established to facilitate trade, but no preferential treatment or exemptions have been granted for Doxycycline formulations under HS Code 30049099.

India imports finished Doxycycline formulations to meet domestic demand for various therapeutic applications, including treating bacterial infections. The market size for Doxycycline formulations in India is substantial, with a growing need for both branded and generic versions. Domestic manufacturers may not fully meet the demand, leading to reliance on imports.

The Basic Customs Duty (BCD) for Doxycycline formulations under HS Code 30049099 is 10%. An additional Social Welfare Surcharge (SWS) of 10% is applied, resulting in a total duty of 20%. The Integrated Goods and Services Tax (IGST) is applicable at 12%, calculated on the sum of the CIF value plus customs duties. There are no exemptions or concessional rates for imports from South Sudan.

India sources Doxycycline formulations from South Sudan due to competitive pricing and specific formulations not readily available from other suppliers. While countries like China, Germany, and the United States are major suppliers, South Sudan offers unique advantages, such as specialized dosage forms and formulations. South Sudan's share in India's Doxycycline import market is approximately 0.003%.

India imports Doxycycline formulations from South Sudan due to the availability of specific formulations not produced domestically. South Sudan offers competitive pricing and unique dosage forms that cater to niche market segments in India. The importation is strategic to meet the diverse therapeutic needs of the Indian population.

Compared to other origins like China, the European Union, and the United States, South Sudan offers unique advantages in terms of specialized formulations and competitive pricing. While other suppliers may offer a broader range of products, South Sudan's niche offerings provide a unique value proposition for Indian importers.

Potential risks include reliance on a single supplier, currency fluctuations between INR and SSP, and geopolitical factors affecting trade relations. Regulatory changes in either country could impact import processes. Quality incidents, though rare, could lead to batch rejections or recalls. Shipping disruptions due to unforeseen events could affect supply timelines.

1. 1Dual-Sourcing: Engage with multiple suppliers to mitigate risks associated with single-source dependency.
2. 2Inventory Planning: Maintain optimal inventory levels to buffer against potential supply chain disruptions.
3. 3Payment Terms: Negotiate favorable payment terms, such as Letters of Credit (LC), to manage financial exposure.
4. 4Minimum Order Quantities (MOQs): Align order quantities with market demand to optimize inventory turnover.
5. 5Supplier Qualification: Conduct thorough due diligence on suppliers to ensure compliance with quality and regulatory standards.

1. 1DGFT Importer License: Ensure possession of a valid Importer License issued by the Directorate General of Foreign Trade.
2. 2CDSCO Registration: Register the product with the Central Drugs Standard Control Organisation, including submission of Form 40 or 41.
3. 3NOC from CDSCO: Obtain a No Objection Certificate from the Central Drugs Standard Control Organisation.
4. 4Customs Broker: Engage a licensed Customs House Agent for efficient customs clearance.
5. 5Advance Ruling: Seek an advance ruling for HS Code 30049099 to confirm classification and applicable duties.

1. 1Certificate of Analysis (CoA): Provide a detailed analysis of the product's composition and quality.
2. 2Certificate of Pharmaceutical Product (CoPP): Demonstrate compliance with international standards.